Agenus sells cut of Incyte, Merck milestone streams

Agenus has sold a portion of the royalties and milestones it is due to receive from Incyte and Merck. Xoma is paying $15 million for one-third of the $600 million in milestones Agenus is in line to pocket and a 10% cut of any royalties.